Preclinical imaging is a cornerstone of translational research, as all therapeutic drugs need to be
tested for efficacy and toxicity on animals prior to human trials. Optical imaging techniques, such as
bioluminescence and multispectral fluorescence imaging, currently dominate preclinical functional
imaging despite their depth dependent limitations on quantitation and sensitivity. Translating drugs
developed with these techniques to clinical models can therefore be difficult. Hence, clinically relevant
nuclear imaging techniques, such as SPECT and PET, are therefore becoming increasingly used in
preclinical imaging. Dedicated preclinical SPECT and PET systems are now available, but for many
preclinical research groups this requires a significant investment in new equipment.